AMGEN and Boehringer Ingelheim said Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager that targets B-cell maturation antigen, a potential target for multiple myeloma. BI 836908 (AMG 420) is currently in phase I studies. Under the agreement, Amgen will work with Boehringer...
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
